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Abstract
Background: Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine (Ser/Thr) kinase
comprising two isoforms, GSK-3a and GSK-3b. Both enzymes are similarly inactivated by serine phosphorylation
(GSK-3a at Ser21 and GSK-3b at Ser9) and activated by tyrosine phosphorylation (GSK-3a at Tyr279 and GSK-3b at
Tyr216). Antibodies raised to phosphopeptides containing the sequences around these phosphorylation sites are
frequently used to provide an indication of the activation state of GSK-3 in cell and tissue extracts. These
antibodies have further been used to determine the subcellular localisation of active and inactive forms of GSK-3,
and the results of those studies support roles for GSK-3 phosphorylation in diverse cellular processes. However, the
specificity of these antibodies in immunocytochemistry has not been addressed in any detail.
Results: Taking advantage of gene silencing technology, we examined the specificity of several commercially
available anti-phosphorylated GSK-3 antibodies. We show that antibodies raised to peptides containing the
phosphorylated Ser21/9 epitope crossreact with unidentified antigens that are highly expressed by mitotic cells
and that mainly localise to spindle poles. In addition, two antibodies raised to peptides containing the
phosphorylated Tyr279/216 epitope recognise an unidentified protein at focal contacts, and a third antibody
recognises a protein found in Ki-67-positive cell nuclei. While the phosphorylated Ser9/21 GSK-3 antibodies also
recognise other proteins whose levels increase in mitotic cells in western blots, the phosphorylated Tyr279/216
antibodies appear to be specific in western blotting. However, we cannot rule out the posssibility that they
recognise very large or very small proteins that might not be detected using a standard western blotting
approach.
Conclusions: Our findings indicate that care should be taken when examining the subcellular localisation of active
or inactive GSK-3 and, furthermore, suggest that the role of GSK-3 phosphorylation in some cellular processes be
reassessed.
Reviewers: Dr. David Kaplan, Dr. Robert Murphy and Dr. Cara Gottardi (nominated by Dr Avinash Bhandoola.)
Background
Glycogen synthase kinase-3 (GSK-3) is a multifunctional
serine/threonine (Ser/Thr) kinase first identified by its
ability to phosphorylate and inactivate glycogen
synthase. Since then, more than fifty substrates have
been identified and GSK-3 has been found to be
involved in multiple cellular functions including protein
synthesis, microtubule organization, cell migration, cell
proliferation, apoptosis and differentiation [1-3]. There
are two isoforms of GSK-3, GSK-3a and GSK-3b, and
there are two splicing variants of the latter, b1 and the
brain-specific isoform, b2, which appears to play a
unique role in axon growth [4]. GSK-3a and GSK-3b
are 98% identical within their kinase domains but they
are not functionally identical, since GSK-3b mutant
mice die during embryonic development [5,6]. In resting
cells, GSK-3 is active, being phosphorylated at a tyrosine
(Tyr) residue in the activation loop (Tyr279 in GSK-3a
and Tyr216 in GSK-3b) [7]. Cell stimulation by several
growth factors activates Akt/PKB, which phosphorylates
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a serine residue close to the amino terminus (Ser21 in
GSK-3a and Ser9 in GSK-3b) to inhibit kinase activity
[8,9]. Other extracellular signals also lead to changes in
GSK-3 localisation or activity, for example, activated G
proteins induce relocalisation and activation of GSK-3
at the membrane [10] and inducers of stress and/or
apoptosis induce GSK-3 tyrosine phosphorylation and
nuclear localisation [11].
GSK-3 activity can be directly assayed in vitro using
kinase assays either in immune precipitates or directly
from extracts [12]. However, these methods are time
consuming and, in practice, GSK-3 activity is frequently
indirectly inferred by western blotting to determine its
phosphorylation state or the phosphorylation state of
known substrates. In addition, immunocytochemistry
using phosphospecific antibodies has been used to
determine the subcellular localisation of active or inac-
tive forms of GSK-3 [13-16]. The correlation between
GSK-3 phosphorylation and kinase activity is well estab-
lished and therefore these approaches are widely used
[17]. The antibodies are raised to short peptides corre-
sponding to phosphorylated sites in GSK-3 and are nor-
mally validated by incubation with the peptide
immunogen, pre-treatment of samples with phosphatase,
or by observing an increase in signal upon stimulation
with factors known to modulate GSK-3 activity, insulin
for Ser9/21 phosphorylation, for example. Although a
loss of signal upon addition of the peptide immunogen
or an increase in the signal after insulin treatment is
indicative of a functional antibody, it does not exclude
recognition of other proteins. Similarly, loss of signal
upon incubation with phosphatase only excludes recog-
nition of unphosphorylated proteins. This potential lack
of selectivity is less of an issue in western blotting since
crossreactivity is often revealed by the apparent molecu-
lar mass of the proteins being detected. In contrast,
when using procedures, such as immunostaining and
flow cytometry, it is crucial to address the issue of selec-
tivity [18-20].
Phosphorylation of GSK-3 at Ser21/9 is mediated by
several members of the AGC family of kinases, including
Akt/PKB [9,21]. Once phosphorylated, this domain of
GSK-3 competes with primed substrates for binding to
the catalytic domain [8]. Thus, it is possible that the
phosphorylated site shares some structural similarity
with primed substrates. In addition, the GSK-3 tyrosine
phosphorylation site is within the activation loop of the
catalytic domain, which is similar in sequence to the
activation loops in other CMGC family kinases. Since
the motifs involved in GSK-3 activation and inactivation
share structural characteristics with other proteins, anti-
bodies recognizing these motifs might be predicted to
recognize those same proteins. Ideally a negative control
is required using cells do not express the protein of
interest. The fact that GSK-3 is ubiquitously expressed
as two isoforms with high sequence homology has made
this difficult to do in the past, but it can now be done
simply, using gene silencing technology.
Taking advantage of RNA interference methods to
specifically silence GSK-3a and/or GSK-3b in 22Rv1
prostate cancer cells, we have examined the specificity
of commonly used anti-pSer and anti-pTyr GSK-3 anti-
bodies. We have found by western blotting that the
anti-pSer antibodies recognise additional proteins, and
by immunofluorescence that both the anti-pSer and the
anti-pTyr GSK-3 antibodies show nonspecific staining.
In summary, our data validate the use of these antibo-
dies for immunoblotting but suggest that they should be
used with care when used for immunocytochemistry.
Results
Silencing of GSK-3a and GSK-3b isoforms using specific
shRNAs
During our studies of the role of GSK-3 in prostate can-
cer, we observed that antibodies raised to phosphorylated
GSK-3 showed contradictory staining patterns, although
each of them was consistent with the technical informa-
tion provided by manufacturers and with previously
published reports. For example, in 22Rv1 cells, mouse
anti-GSK-3b (pY216) from BD shows bright nuclear
staining similar to that on the data sheet, whereas the
rabbit anti-GSK-3a/b (pY279/216) from Merck shows
staining at focal adhesions, as previously reported [22].
Noting that the sequences surrounding pY279 in GSK-
3a and pY216 in GSK-3b are identical, these results sug-
gest either that each antibody recognises a different pool
of tyrosine-phosphorylated GSK-3 or that they bind to
different proteins, which raises questions about their spe-
cificity. To address this, we silenced GSK-3a and/or
GSK-3b in 22Rv1 cells by transfecting shRNAs targeting
specific GSK-3 isoforms [4]. As expected, immunoblot-
ting showed a reduction in the expression levels of the
targeted GSK-3 isoforms when compared to shRNA con-
trols (Figure 1A, B). Similar reductions in the levels of
phosphorylated GSK-3 were detected when probing with
anti-GSK-3a/b (pS21/9), anti-GSK-3a (pS21), anti-GSK-
3a/b (pY279/216) and anti-GSK-3b (pY216) (Figure 1A).
These results indicate efficient reduction of GSK-3 levels
and validate the use of these antibodies for immunoblot-
ing. Silencing of specific GSK-3 isoforms was further
confirmed by immunofluorescence. GSK-3a, but not
GSK-3b, staining intensity was reduced in cells co-trans-
fected with eGFP plasmid and shRNAs targeting GSK-3a
(GFP+) compared to adjacent non-transfected cells
(GFP-) (Figure 1C). In addition, GSK-3b but not GSK-3a
staining was reduced in cells co-transfected with shRNAs
targeting GSK-3b (GFP+) compared to adjacent non-
transfected cells (GFP-) (Figure 1D) and, finally, in both
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cases fluorescence intensity was just above background
levels in cells co-transfected with eGFP plasmid (GFP+)
and shRNAs targeting each of GSK-3a and GSK-3b,
whereas it was high in adjacent non-transfected cells
(GFP-) (Figure 1E). In control experiments over 90% of
GFP-positive cells co-expressed the shRNA plasmid, as
reflected by a reduction in the expression level of the tar-
get protein (Additional file 1). It should be noted that not
all of the cells that survived the short treatment with pur-
omycin were transfected (we estimate 30%). The extracts
are therefore derived from a mixture of transfected and
non-transfected cells, whereas the images shown are of
transfected cells in which GSK-3 was downregulated.
This explains the apparent discrepency between the
observed decreases in expression by western analysis and
by immunocytochemistry.
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Figure 1 Silencing of GSK-3 isoforms in 22Rv1 cells. (A) 22Rv1 cells were transfected with the indicated shRNAs and then selected with
puromycin, as described in the Methods. After 72 hours, total cell extracts (20 μg) were prepared and probed by western blotting using the
indicated phosphospecific antibodies and then stripped and reprobed with a mixture of antibodies to GSK-3a, GSK-3b and HSP60 (top panel).
(B) Expression of GSK-3 normalized to HSP60. (C-E) Cells were co-transfected with a combination of eGFP and the pSM2 plasmids ash1 and ash2
(C), bsh1 and bsh2 (D) or ash2 and bsh2 (E). 72 hours after transfection, cells were fixed and stained with anti-GSK-3a or anti-GSK-3b
monoclonal antibodies and analyzed by confocal microscopy. Arrowheads indicate GFP+ cells in which GSK-3a or GSK-3b are silenced and
asterisks indicate GFP+ cells with the same level of protein expression as neighbouring cells. Scale bars = 50 μm.
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Anti-pSer GSK-3 antibodies recognise unidentified
antigens in mitotic cells
Once we had confirmed the specific silencing of GSK-3
isoforms, we addressed questions about the selectivity of
the different anti-phosphorylated GSK-3 antibodies.
First, we examined the selectivity of anti-GSK-3a/b
(pS21/9) and anti-GSK-3a (pS21) (Cell Signalling Tech-
nology). Both antibodies similarly stained cells strongly
in all phases of mitosis, with the intensity of the staining
highest at the spindle poles (Figure 2A, B), suggesting a
possible role for GSK-3 during spindle dynamics, as pre-
viously reported by Wakefield et al. [13], who used one
of these antibodies. However, when cells were co-
transfected with shRNAs targeting both GSK-3a and
GSK-3b, there was no difference in the staining intensity
in transfected mitotic cells compared with adjacent
untransfected cells (Figure 2C). In this figure transfected
cells are in green, total GSK-3 in red and the antigen
detected by anti-GSK-3a/b (pS21/9) in white. As
expected, the level of GSK-3 was reduced in all trans-
fected (GFP+) cells, mitotic and non-mitotic. However,
the arrows indicate two GSK-3-negative cells in mitosis
that are strongly stained by the GSK-3a/b (pS21/9) anti-
body. Similar results were obtained using anti-GSK-3a
(pS21). In the example shown (Figure 2D), the arrows
indicate two cells in mitosis, one that expresses GSK-3
and the other that does not, yet both are recognised by
the anti-GSK-3a (pS21) antibody. Thus, the antigen
detected by anti-pSer antibodies in mitotic cells is not
GSK-3 but presumably another phosphoprotein whose
level of expression is increased at mitosis. In fact, wes-
tern blotting of cell extracts from 22Rv1 cells synchro-
nized at G2/M by treatment with nocodazole revealed
several higher molecular weight proteins that were spe-
cifically recognised by anti-pSer GSK-3 antibodies, but
not by anti-pTyr GSK-3 or total GSK-3 antibodies
(Figure 2E). In addition, serum starvation, which is
expected to reduce the proportion of cells in mitosis,
reduced the signal of the crossreacting antigens. As
expected, serum starvation reduced phosphorylation at
Ser9/21, most likely through a reduction in Akt/PKB activ-
ity, but did not affect GSK-3 phosphorylation at Tyr216/
279. Interestingly, although the antigen detected at spindle
poles in mitotic cells is not GSK-3, western blots revealed
an increase in the pSer21 GSK-3a signal in nocodazole-
treated cells, and this correlated with an increase in b-
catenin/Tcf transcriptional activity during mitosis (Figure
2F), as previously reported by Davidson et al. [23].
Anti-pTyr GSK-3 antibodies recognise unidentified
antigens in the nucleus and in putative focal adhesions
Next, we investigated the selectivity of a mouse mono-
clonal anti-phosphotyrosine GSK-3b antibody (BD) and
two rabbit polyclonal antibodies: anti-GSK3a/b (Y279/
216) (Abcam and Merck) and observed quite different
staining patterns: the monoclonal antibody showed
strong nuclear staining (Figure 3A), whereas both poly-
clonal antibodies stained what appeared to be focal con-
tacts (Figure 3C, D and Additional file 2); in all cases
faint cytosolic staining was also observed. Not all nuclei
stained with the anti-GSK-3b (pY216) mouse monoclo-
nal antibody, but those that did were also positive for
Ki-67, indicating that they are proliferating cells
(Figure 3A). In the case of the anti-GSK3a/b (pY279/216)
antibodies, the staining, although variable from cell to cell,
was usually localised to one end of each cell (Figure 3C),
suggesting that the antigen recognised is expressed by
migrating cells. When cells were co-transfected with GFP
plasmid and shRNAs targeting both GSK-3a and GSK-3b
there was no change in the intensity of the nuclear stain-
ing observed using the anti-GSK-3b (pY216) monoclonal
antibody (Figure 3B, arrowheads), or in the polarised cyto-
solic staining observed using the anti-GSK-3a/b (pY279/
216) polyclonal antibodies in transfected cells (Figure 3D,
arrowhead and Additional file 2) compared to control
cells. However, there was a reduction in the intensity of
the weak cytosolic staining in both cases (Figure 3B, D;
note the pseudocolour scales for relative signal intensities).
These data strongly suggest that the antigens recognised
in the nucleus and at putative focal contacts by these anti-
bodies are not GSK-3, and that only the weak cytoplasmic
staining, where GSK-3a and GSK-3b can be detected
using specific antibodies, represent tyrosine-phosphory-
lated GSK-3.
Discussion
Several growth factors activate Akt/PKB to inhibit GSK-3
by inducing phosphorylation at Ser21/9 [9] and other
external stimuli have been show to increase phosphoryla-
tion at Tyr279/216, which is required for GSK-3 activity
[7,16,24]. Thus, the phosphorylation state of GSK-3 is
widely used to provide an indication of its activity; indeed
several companies provide kits to measure GSK-3 activity
based on the level of Ser21/9 phosphorylation. Most
commercial suppliers sell antibodies raised to short GSK-
3-based phosphopeptides that are validated to differing
degrees, but include competition with blocking peptide,
loss of signal upon treatment with a phosphatase and
increased signal after growth factor stimulation. How-
ever, these assays do not eliminate the possibility that the
antibodies recognise other phosphoproteins.
Using shRNAs to silence GSK-3a, b or both, we
checked the selectivity of five different antibodies. Our
results indicate that all detected phosphorylated GSK-3
by immunoblotting, with relatively weak binding to other
proteins. Anti-GSK-3a/b (pS21/9) and anti-GSK-3a
(pS21) recognised nonspecific bands, particularly in
extracts from cells treated with nocodazole, but in both
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Figure 2 Anti-GSK-3a/b pS21/9 and anti-GSK-3a pS21 recognise an unidentified antigen in mitotic cells. (A and B) 22Rv1 cells cultured in
normal media growing at 60-70% confluence were fixed and stained with anti-GSK3a/b (pS21/9) (red) and anti-tubulin (green) (A) or with anti-GSK-
3a pS21 (red) (B); note the strong staining of mitotic cells by the pS21/9 antibodies (arrowheads). (C and D) Cells were co-transfected with eGFP,
ash2 and bsh2 plasmids and, after 72 h, fixed and stained using a mix of anti-GSK3a and anti-GSK-3b monoclonal antibodies (C and D, red) and
anti-GSK-3a/b pS21/9 (C) or anti-GSK-3a pS21 (D) (both far-red, shown in white). Confocal images were obtained as described in the Methods.
Arrowheads indicate mitotic transfected (GFP+) cells and asterisks indicate mitotic non-transfected cells (GFP-). In (C) and (D) the bottom right
panels show DIC images of the cells. (E) Extracts from cells were cultured in medium containing 0.5% serum, normal medium (10% serum) or
normal medium containing nocodazole for 18 h were probed using the indicated antibodies. Asterisks mark nonspecific antigens upregulated in
nocodazole treated cells. (F) 22Rv1 cells were transfected with 100 ng TopFlash or FopFlash luciferase reporters and 15 ng pGL3 Renilla luciferase,
cultured for an additional 12 h in the absence or presence of nocodazole (300 ng/ml) and then stimulated with recombinant Wnt3a (R&D Systems,
100 ng/ml) for 8 h. Firefly luciferase activity was normalised using Renilla luciferase activity. Scale bars: A, C, D = 50 μm; B = 25 μm.
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cases these could be distinguished from GSK-3 by their
molecular masses. In contrast, when the antibodies were
used for immunofluorescence, there were three clear
instances where they did not perform as expected. First,
anti-GSK-3a/b (pS21/9) and anti-GSK-3a (pS21) both
associated with unidentified proteins localised at the
spindle poles of mitotic cells. This correlated with the
appearance of the nonspecific bands in cells treated with
nocodazole, suggesting that they recognise phosphopro-
teins involved in mitosis. Interestingly, the same anti-
GSK-3a/b (pS21/9) antibody has been used previously to
localise GSK-3 at the spindle poles of mitotic cells and to
Ki67
pY216 GSK-3?
DAPI
A B
C D 
GSK-3
pY279/216 GSK-3?/?
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Lower
plane
Middle plane 
pY216 GSK-3? (red) 
pY279/216 GSK-3?/? (white) 
Lower 
 Plane 
Figure 3 Anti-GSK-3 pTyr antibodies recognise additional antigens in cell nuclei and at cell borders. (A) 22Rv1 cells cultured in normal
medium until they reached 60-70% confluence were fixed and stained with anti-GSK3b (pY216) antibody (red) and anti-Ki67 (green); (B) Cells were
co-transfected with a eGFP, ash2 and bsh2 plasmids and, after 72 h, fixed and stained using anti-GSK-3b pY216 (red). Transfected cells are shown in
green (indicated by arrowheads). Long exposures of the red channel (top and bottom images in middle and top right image) were taken to show
that the weak cytoplasmic signal detected by anti-GSK-3b pY216 is reduced in transfected cells (best observed in the top right panel by comparing
the signal intensity in the cytoplasm of transfected cells with that in nearby untransfected cells, refer to the adjacent pseudocolor scale). (C and D)
Untransfected cells (C) or cells transfected with eGFP, ash2 and bsh2 plasmids (D) were fixed and stained using a mix of anti-GSK-3a and anti-GSK-
3b monoclonal antibodies (red) and anti-GSK-3a/b pY279/216 from Abcam (far red, shown as white in GFP transfected cells). Images were
obtained using a confocal microscope as described in the Methods. In (C) the pY279/216 antibody staining of putative focal contacts is clearest in
the lower focal plane (arrowhead), whereas total GSK-3 (red) staining is diffuse. The arrowhead in (D) indicates a transfected (GFP+) cell that does
not express GSK-3 but is stained at putative focal contacts using the pY279/216 antibody. The inset shows this staining at a focal plane closer to
the coverslip. In (B) and (D) the bottom right panels show DIC images of the cells. Scale Bars = 50 μm.
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provide evidence to support a role for GSK-3 inactivation
during chromosome alignment [13]. This contrasts with
recent reports which indicate that GSK-3b inhibition
causes defects in chromosome alignment [25-27], and
thus suggesting that active rather than inactive GSK-3 is
required for proper spindle formation. Second, the anti-
GSK-3b (pY216) monoclonal antibody showed weak
cytoplasmic staining and strong nuclear staining in
22Rv1 cells. However, only the weaker staining in the
cytoplasm was reduced upon GSK-3 depletion. Active
GSK-3 can be found in the nucleus in some cells, where
it phosphorylates cyclin D1 and promotes its nuclear
export, thus inhibiting proliferation [28]. However, the
nuclear staining observed using the GSK-3 (pY216)
monoclonal antibody was observed in Ki67-positive cells
and did not correlate with the cytoplasmic staining
observed using GSK-3a and GSK-3b antibodies. Finally,
we observed that the anti-GSK-3 a/b (pY279/216) anti-
bodies from Abcam and Merck recognised what appear
to be focal contacts. Again, this signal was not reduced in
GSK-3-silenced cells, where we only observed a decrease
in the weak cytoplasmic staining. Immunofluorescence
studies have been used to show that tyrosine-phosphory-
lated GSK-3 localises to focal adhesions [14,15]. In con-
trast, our data suggest that tyrosine-phosphorylated
GSK-3 is evenly distributed, similar to GSK-3 itself.
Conclusions
While our data support the use of phosphospecific GSK-
3 antibodies to monitor the phosphorylation state of
GSK-3 in cell extracts, they raise doubts about results
obtained using these antibodies to study subcellular
localisation. The nonspecific recognition of phosphory-
lated epitopes may prove to be a common issue for anti-
bodies raised to regulatory and target sites of protein
kinases that have many substrates.
Methods
Cell Culture, plasmids and transfections
22Rv1 cells (ATCC) were cultured in RPMI/DMEM (1:1)
(Gibco) supplemented with 20% FCS and penicillin
(100 U/mL) streptomycin (100 μg/mL) at 37°C and 5%
CO2. Cells were passaged when they reached 70-80%
confluence at 1:5-6 with 0.05% trypsin. The shRNAmir
pSM2 plasmids (OpenBiosystems, Madrid, Spain) have
been described previously [4]. Cells were transfected for
3-4 h in OptiMEM (Invitrogen) using Lipofectamine Plus
(Invitrogen). For western blots, 5 × 105 cells were trans-
fected using 1.5 μg DNA (0.75 μg of each shRNA plas-
mid), 10 μL of Plus reagent and 5 μL of Lipofectamine.
After 14-16 h, puromycin (1 μg/ml) was added and cells
were grown for 3 d prior to lysis in radioimmunoprecipi-
tation assay (RIPA) buffer. For immunofluorescence, 105
cells were plated on collagen-coated coverslips and trans-
fected with 150 ng of each pSM2 plasmid plus 50 ng
pEGFP (Clontech) using 2 μl Plus reagent and 1 μl Lipo-
fectamine, cultured for 72 h and then fixed.
Immunofluorescence
Cells were fixed in 4% paraformaldehyde (PFA) for
15 min and permeabilised with 0.1% Triton for 15 min
at room temperature, nonspecific binding was blocked
for at least 30 min using blocking buffer (PBS, 50 mM
glycine, 2% bovine serum albumin (BSA), 0.01% sodium
azide). Next, cells were incubated for 2 h with primary
antibodies (Table 1) in wash buffer (blocking buffer
diluted 1:10 in PBS), washed four times, 5 min each,
and incubated with Cy3 or Cy5 anti-mouse IgG and
Texas Red anti-rabbit IgG donkey antibodies diluted
1:500 in wash buffer. After washing again, the coverslips
were mounted using Vectashield® (Vector Labs, Burlin-
game) containing 4’,6-diamidino-2-phenylindole (DAPI,
1.5 μg/mL), and wide-field epifluorescence images were
acquired at room temperature on an upright fluores-
cence microscope (AxioimagerD1; Carl Zeiss, Inc.) using
a 40 × 0.75 NA objective (Figures 2A and 3A) an a
HRm camera and Axiovision 4.8 acquisition software.
Confocal images (Figures 1, 2B-D and 3B-D), were
acquired at room temperature on a DM IRE2 laser scan
microscope (Leica) with a 63 × 1.4 NA objective, an
optimised pinhole and x2 electronic zoom using LCS
acquisition software. Images are presented after digital
Table 1 list of antibodies used
Antibody Western IF Source
Anti- GSK-3a mouse monoclonal antibody 1:5000 1:500 Santa Cruz (sc-5264)
Anti- GSK-3b mouse monoclonal antibody 1:5000 1:500 BD Biosciences (610202)
Anti- phospho Ser21-GSK-3a rabbit monoclonal antibody 1:1000 1:100 Cell Signalling (9316)
Anti- phospho Ser21/9-GSK-3a/b rabbit polyclonal antibody 1:1000 1:100 Cell Signalling (9331)
Anti- phospho Tyr216-GSK-3b mouse monoclonal antibody 1:1000 1:100 BD Biosciences (612313)
Anti- phospho Tyr279/216-GSK-3a/b rabbit polyclonal antibody 1:1000 1:100 Abcam (ab52188)
Anti- phospho Tyr279/216-GSK-3a/b rabbit polyclonal antibody 1:1000 1:100 Merck (ST1013)
Anti- tubulin mouse monoclonal antibody N.A. 1:100 Chemicon (CBL412)
Anti- Ki67 rabbit polyclonal antibody N.A. 1:100 Abcam (ab833)
Campa and Kypta Biology Direct 2011, 6:4
http://www.biology-direct.com/content/6/1/4
Page 7 of 9
adjustment of curve levels (gamma) to maximize signal
with ImageJ software. In all cases, exposure times and
digital manipulation were the same for control and
experimental samples. Fluorochromes and colours are as
indicated in the figure legends.
Western blot analysis
Lysates were prepared by incubating cells on ice for
5 min in RIPA buffer [29], cleared by centrifugation, fro-
zen and stored at -80°C and then thawed again at 4°C.
Protein concentration was determined by the Lowry
method and 20 μg per lane of lysate was resolved by
10% SDS-polyacrylamide gel electrophoresis (PAGE) and
transferred onto Protran® (Whatman) nitrocellulose
membranes. Nonspecific binding was blocked by 1 hour
incubation with blocking buffer before membranes were
probed overnight at 4°C with primary antibodies diluted
in blocking buffer (3% BSA in Tris-buffered saline with
0.1% Tween-20 (TBS-T)). After extensive washing with
TBS-T, specific bands were detected on Hyperfilm™
(GE Healthcare) using horseradish peroxidase (HRP)-
conjugated donkey secondary antibodies (1:10,000;
Jackson Labs) and the ECL detection system (GE
Healthcare). Primary antibodies are listed in Table I.
Additional material
Additional file 1: Supplemental Figure 1. Coexpression of GFP and
shRNA plasmids. 22Rv1 cells were transfected with a combination of
the ash2, bsh2 and eGFP plasmids. 72 hours after transfection, cells were
fixed and stained with anti-GSK-3a or anti-GSK-3b monoclonal antibodies
(red) and analyzed by fluorescence microscopy. Scale bars = 100 μm.
Additional file 2: Supplemental Video. Z-series of images to visualise
nonspecific antigens detected by anti-PTyr GSK-3 antibodies. Cells
transfected with eGFP, ash2 and bsh2 plasmids were fixed and stained
using anti-GSK-3a + anti-GSK-3b monoclonal antibodies (red) and anti-GSK-
3a/b pY279/216 from Merk (far red, shown as white in GFP transfected
cells). Images were obtained using a confocal microscope as described in
the Methods. The video shows a Z-stack of 5 optical sections from bottom
(surface contact with coverslip) to top.
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Reviewers’ comments and authors’ responses
Reviewer 1
Dr. David Kaplan
Department of Pathology, Case Western Reserve University
This manuscript exposes an important issue that has not been adequately
considered or accounted for. Antibody probes can be used in unintended
ways which have not been validated and this inappropriate use results in
artifactual findings. In the submitted manuscript, the authors demonstrate
that antibodies validated for western analysis but not verified for
immunohistochemistry give aberrant results in immunohistochemistry. The
results obtained by the inappropriate use of the antibodies mislead the
community and should be guarded against. The manuscript submitted
demonstrates this important and essential circumstance. Considering the
prevalence of the use of antibodies as probes, it is likely that this problem is
widespread.
It may be interesting for the authors to review a manuscript I published in
1998 [30]. In this manuscript we described an antibody that have been
validated for western analysis but was used inappropriately in flow
cytometry. Using transfectants, we showed that the antibodies gave
aberrant results in flow cytometry. The findings we made involving flow
cytometry are similar to the findings in this manuscript involving
immunohistochemistry.
I have a single major concern with the manuscript as presently written. The
descriptions in the text and the legends for Figure 2 and 3 are not clear. For
instance, in Figure 2C there are 6 panels but the various procedures
associated with each of the panels is not clear to me. Also, in the legend
there is a reference to asterisks but there are no asterisks in the figure. These
data are crucial for the manuscript. The impact would be greatly improved
by clarifying the description of these results.
Another concern that I think may be valuable to address involves Figure 1. I
notice that the decrease in expression by western analysis seems to be
significantly less than the decrease in expression by immunohistochemistry.
By westerns the decrease is around 50% but the decrease by
immunohistochemistry appears to be complete. It may be valuable to
comment on this apparent discrepancy.
Authors’ responses
We note the work by Smith et al. and have cited that paper as a good
example of antibodies producing aberrant results in flow cytometry. The
legends and text referring to Figures 2 and 3 have been revised to clarify
the procedures followed, and the missing asterisk has been added. Finally,
we have commented on the apparent discrepancy in Figure 1, which results
from the fact that, even after puromycin selection, not all of the cells (we
estimate 30%) that survive the short treatment with puromycin are
transfected. The extracts are therefore derived from a mixture of transfected
and non-transfected cells, whereas the images shown are of transfected cells
in which GSK-3 was downregulated.
Reviewer 2
Dr. Robert Murphy
Center for Bioimage Informatics, Carnegie-Melon University, Pittsburgh
This manuscript describes characterization of phosphospecific antibodies
against GSK-3. These include antibodies previously used for a number of
studies aimed at localizing phosophorylated isoforms of GSK-3. When
expression of these isoforms was inhibited by shRNA transfection, expected
reduction in antibody staining was not observed. While the quality of the
immunofluorescence images might have been higher, the results
appropriately raise concerns about the interpretation of prior experiments
using the antibodies for localization studies. Since these antibodies appear to
be monospecific in western blots, the explanation for the results is unclear.
Recommended revisions
The manuscript states that “The majority of these antibodies appear to be
specific when used for western blotting, suggesting that the sequences
containing phosphorylated Ser21/9 and Tyr279/216 form conformational
epitopes found in other phosphoproteins.” It is hard to understand what is
meant by this, at least for the monoclonal antibodies. If the authors believe
that one of the monoclonal antibodies actually recognizes a conformational
epitope (and therefore recognizes more than one protein), how can it also
be recognizing the specific denatured protein? It seems that it should either
not recognize any of the denatured proteins, or should recognize them all
similarly (indicating that the epitope does not change much when the
protein is denatured). It would be helpful to have more clarification on this
issue. The legend to figure 1 is not clear - what is the top panel? Does it
show a mix of antibodies against HSP60 and GSK3-alpha and beta?
Authors’ responses
We agree with Dr. Murphy that, in the case of the monoclonal antibodies,
this was an incorrect use of ‘conformational epitope’. Since four of the
antibodies tested are polyclonal, it may still be the case for those antibodies,
but for clarity we have removed this term. We have added that it is possible
that the crossreacting proteins might be too small or too large to detect by
standard PAGE/western blotting. In addition, we have clarified the legend to
Figure 1, where blots were indeed probed with the indicated
phosphospecific antibodies and then stripped and reprobed with a mix of
antibodies to GSK-3a, GSK-3b and HSP60.
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Reviewer 3
Dr. Cara Gottardi (nominated by Dr Avinash Bhandoola)
Northwestern University, Chicago
This manuscript clearly demonstrates that commercially available antibodies
to phospho-GSKa and b can be used for immunoblot analysis, but that
microtubule and focal adhesion staining patterns are due to phospho-
epitope cross reaction with non- GSK antigens. Since a number of papers
have used these antibodies incorrectly, and with the controls provided in
this study, I think the manuscript is worthy. Overall well written, clear figures
and concise.
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